Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1829 clinical trials
featured
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been

solid tumor
solid tumors
  • 51 views
  • 14 Dec, 2020
  • 53 locations
featured
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Carcinoma

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

cancer
solid tumors
  • 25 views
  • 14 Dec, 2020
  • 9 locations
featured
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

solid tumor
solid tumors
  • 268 views
  • 08 Dec, 2020
  • 11 locations
featured
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

advanced solid tumor
solid tumor
malignant solid tumor
solid tumors
  • 448 views
  • 25 Aug, 2021
  • 11 locations
featured
QUILT -2.023: A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC

This is a phase 2, open-label, randomized study to compare the safety and efficacy of combination therapy with ALT-803 and pembrolizumab (experimental arm) versus pembrolizumab alone (control arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.

  • 2 views
  • 31 Mar, 2021
  • 1 location
featured
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.  

solid tumor
solid tumors
metastatic cancer
cancer
measurable disease
  • 38 views
  • 14 Dec, 2020
  • 13 locations
featured
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)

This clinical study aims to investigate if impairment of the deoxyribonucleic acid damage repair (DDR) pathway by the Elimusertib in combination with blockade of the PD-1/PD-L1 pathway by pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk …

EGFR
pembrolizumab
measurable disease
  • 1 views
  • 14 Sep, 2021
  • 10 locations
featured
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of two phases, a Dose

primary cancer
cancer
endometrial carcinoma
measurable disease
  • 229 views
  • 14 Dec, 2020
  • 16 locations
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor

FGFR2
malignancies
primary cancer
cancer
metastasis
  • 46 views
  • 25 Aug, 2021
  • 57 locations
featured
An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

advanced solid tumor
solid tumor
solid tumors
  • 80 views
  • 08 Dec, 2020
  • 7 locations